KOSDAQBiotech & Pharma456160

G2GBIO

₩33,750▲ 5.14%2026-11-18 close
Market Cap
₩561.2B
Turnover
₩5.3B
Volume
150K
Shares out.
16.6M
PER
—
PBR
—
EPS
-₩1,460
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses persist; partnerships and Plant 2 are the test

G2GBIO has recorded operating losses for three straight years, with 2025 revenue of KRW 423 million and an operating loss of KRW 12.2 billion. Whether the KRW 150 billion raised in February 2026 and the second GMP plant translate into licensing and contract revenue is the central question.

  1. 1

    2025 revenue was KRW 423 million, down 45.0% year on year, and the operating loss widened to KRW 12.2 billion.

  2. 2

    The 2026 third-quarter operating loss was KRW 3.43 billion and the net loss attributable to controlling shareholders was KRW 6.43 billion, extending the run of losses to five quarters, with the controlling-shareholder net loss larger than in the prior quarter.

  3. 3

    In February 2026 the company raised KRW 150 billion through a third-party allotment of convertible preferred shares and a private convertible bond, of which KRW 60 billion is earmarked for the second GMP plant.

  4. 4

    Revenue in 2024 came from licensing and clinical services, CDO/CDMO work and joint development, and exports accounted for 64.1% of 2025 revenue.

  5. 5

    Because the company has posted net losses over the last four quarters, PER cannot be calculated, and valuation discussion centers on pipeline and partnership results.

02

Business structure

G2GBIO, founded in 2017, develops long-acting injectable drugs built on its proprietary microsphere technology, InnoLAMP. The platform aims to improve both drug duration and dosing convenience and targets indications with low medication adherence, such as dementia, obesity and schizophrenia.

The 2024 revenue mix was 36.8% from licensing and clinical services, 38.6% from CDO/CDMO work and 24.6% from joint development and research services, according to Sisa Journal.

Exports accounted for 64.1% of 2025 revenue, versus 63.2% in 2024, based on the regional breakdown in the annual report as compiled by a data service. The dementia candidate GB-5001 has completed Phase 1 in a one-month sustained-release formulation and is licensed to two domestic pharmaceutical companies.

The semaglutide-based obesity candidates GB-7001/3 are in preclinical development, and schizophrenia and hair-loss candidates have entered Phase 1. The company signed a formulation co-development deal with Boehringer Ingelheim in January 2025, followed by an additional agreement in July of the same year.

It has a co-development agreement with Global Company A premised on technology transfer and a CDO contract with Global Company C. A single-molecule semaglutide obesity program was reported at an investor briefing as licensed to a Samsung Epis Holdings group company.

Peptron, which works in the same long-acting drug delivery field, has a collaboration with Eli Lilly, so competition here centers as much on securing partners as on the technology itself.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩58,461,532-₩3.6B−6098.1%
2025Q4₩200M-₩3B−1485.0%
2026Q1₩400M-₩3.3B−944.6%
2026Q2₩1.6B-₩2.7B−168.6%
2026Q3₩400M-₩3.4B−978.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩700M-₩13.1B-₩10.5B−1776.7%—−182.4%
2024₩800M-₩10.8B-₩83.3B−1399.8%—−121.2%
2025₩400M-₩12.2B-₩12.1B−2884.2%−20.7%16.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue was KRW 740 million in 2023, KRW 769 million in 2024 (up 3.9% year on year) and KRW 423 million in 2025 (down 45.0% year on year). Of 2023 to 2025, 2024 was the largest year and 2025 the smallest.

The operating loss was KRW 13.1 billion in 2023, KRW 10.8 billion in 2024 (losses continued but narrowed) and KRW 12.2 billion in 2025 (losses continued and widened).

The operating margin was -1,776.7% in 2023, -1,399.8% in 2024 and -2,884.2% in 2025, so the deepest margin loss came in the year with the smallest revenue. The net loss attributable to controlling shareholders was KRW 10.5 billion in 2023, KRW 83.3 billion in 2024 and KRW 12.1 billion in 2025.

One data service attributed most of the 2024 loss to a one-off valuation loss. The net loss including non-controlling interests was reported as KRW 10.5 billion, KRW 83.3 billion and KRW 12.1 billion for the same years.

The debt-to-equity ratio was -182.4% in 2023 and -121.2% in 2024, negative because total equity was below zero in those years. It turned positive at 16.1% in 2025, when total equity stood at KRW 58.3 billion and total liabilities at KRW 9.41 billion.

Operating cash flow was -KRW 11 billion in 2023, -KRW 7.97 billion in 2024 and -KRW 13.9 billion in 2025, so the cash outflow in 2025 exceeded the operating loss.

Quarterly revenue ran at KRW 58.46 million in the third quarter of 2025, KRW 203 million in the fourth quarter, KRW 351 million in the first quarter of 2026, KRW 1.6 billion in the second quarter and KRW 351 million in the third quarter. Second-quarter 2026 revenue was the highest of the last five quarters.

Over the same span the operating loss stayed between KRW 2.7 billion and KRW 3.57 billion, while the net loss attributable to controlling shareholders grew to KRW 5.54 billion, KRW 5.71 billion and KRW 6.43 billion in the first three quarters of 2026. The four-quarter total for that net loss is KRW 20.5 billion.

The gap between operating loss and the controlling-shareholder net loss widened, and the quarterly filings alone do not pin down its cause, so the annual report should be checked for non-operating items.

05

Industry analysis

The long-acting injectable market is driven by demand for fewer doses and better adherence. In obesity and diabetes care, extending dosing intervals for GLP-1 class injectables is a central theme.

In its own PK simulation, the company said the peak-to-trough concentration ratio of its semaglutide formulation was 1.3 times, lower than the 1.8 times cited for Ozempic and Wegovy. Several biotech companies with similar technology are already in the market, so differentiation is a challenge.

One analysis holds that the valuation of Korean DDS companies depends on which global pharmaceutical company they partner with, and Peptron's rise as an Eli Lilly partner is often cited as an example. G2GBIO is mentioned as the next name in the same group through its work with Boehringer Ingelheim.

Revenue of about KRW 423 million in 2025 means the licensing cycle is not yet reflected in the revenue base. On the CDMO side, in-house GMP capacity suited to large-volume demand from global pharmaceutical companies is presented as a competitive requirement. Compared with larger CDMO companies in the sector, its production scale and track record remain small.

06

Outlook

The confirmed plans focus on production capacity. Of the funds raised in February 2026, KRW 60 billion goes to building the second GMP plant in Osong, Chungbuk, with investment running from 2026 through 2027. The target completion for commercial production is 2027.

The second plant is planned to include a prefilled syringe line and a dual small-molecule and peptide line, and the first plant will add a semaglutide-based injectable line. The stated goal is capacity for roughly 7 million doses per year once complete.

On the clinical side, the company set a target of entering clinic with a one-month semaglutide formulation in the first half of 2026, and whether that happened should be confirmed through disclosures and reports. Reports also said the company was preparing to enter a multiple-dose Phase 1b study of GB-5001.

The securities filing made at listing projected revenue of KRW 30.2 billion and operating profit of KRW 10 billion in 2027, with a turn to profit tied to licensing and CDO work, and also projected KRW 72.5 billion in revenue and KRW 41.3 billion in operating profit for 2029.

These are listing-date projections and sit far from the KRW 423 million in 2025 revenue. A conversion price adjustment for the sixth convertible bond round was disclosed on September 23, 2026.

07

Valuation

PER
—
PBR
—
ROE
-21.4%
EPS
-₩1,460
BPS
—
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, PER cannot be calculated. The company pays no dividend, so its dividend yield sits below the sector average and a dividend-based comparison does not apply.

Market capitalization is far above total equity of KRW 58.3 billion at the end of 2025, placing the stock in a range of high premium to net assets. That gap reflects expectations for pipeline and licensing results rather than current earnings.

A valuation analysis of Korean DDS companies also weights the obesity-drug business development results, and generating revenue from commercial products is flagged as the next hurdle.

The listing-date projections assumed a turn to profit in 2027, but given the recent loss amounts and quarterly revenue swings, the distance between those projections and reported results remains wide. Valuation is best read by placing market value, net assets and the stage of partner agreements side by side.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Wider partner base

The company signed a formulation co-development deal with Boehringer Ingelheim in January 2025, followed by an additional agreement that July. GB-5001 is licensed to two domestic pharmaceutical companies, and it has a co-development deal with Global Company A and a CDO contract with Global Company C. As the partner count grows, there is more room for contract revenue to show up in reported results.

Production capacity build-out

KRW 60 billion is allocated to the second GMP plant, with commercial production targeted for completion in 2027. The plant is planned to include a prefilled syringe line and a dual small-molecule and peptide line, targeting capacity for about 7 million doses per year.

The company describes the facility as the base for meeting large-volume demand from global pharmaceutical companies.

Funding headroom and obesity formulation

The February 2026 raise of KRW 150 billion substantially expanded liquidity, and net cash at the end of the second quarter of 2026 was reported at KRW 74.8 billion by a data service based on the semi-annual report.

In its own simulation, the company said the peak-to-trough ratio of its semaglutide formulation was 1.3 times, below 1.8 times for Ozempic and Wegovy. The figure rests on the company's own preclinical and PK data, and clinical validation remains to be seen.

09

Bear factors

Thin revenue base

2025 revenue was KRW 423 million, down 45.0% year on year, and the operating loss widened to KRW 12.2 billion. Quarterly revenue in 2026 ranged between KRW 351 million and KRW 1.6 billion, and the third quarter fell 78.1% from the prior quarter.

Because revenue depends on when contracts are recognized, the predictability of results is low, which is a bearish factor.

Widening losses and dilution

The net loss attributable to controlling shareholders grew each quarter in 2026, reaching KRW 5.54 billion, KRW 5.71 billion and KRW 6.43 billion. The four-quarter total is KRW 20.5 billion. A financial media outlet noted that the largest shareholder's stake is small, so large fundraising can add dilution pressure.

Early clinical stage

A 2025 analytical report noted that the main pipeline is still at an early clinical stage. The dementia candidate GB-5001 has completed Phase 1 but needs further clinical stages before commercialization.

The semaglutide-based obesity candidate is in preclinical development, and clinical entry for the one-month formulation was presented as a target in reporting at the time.

10

Risk factors

Funding and dilution risk

The February 2026 financing consisted of a third-party allotment of convertible preferred shares and a private convertible bond, each worth KRW 75 billion. Conversions would increase the common share count and dilute existing holders.

Because a conversion price adjustment was disclosed on September 23, 2026, changes to conversion terms need ongoing tracking.

Clinical and development risk

Multiple-dose safety results for GB-5001 and clinical entry for the semaglutide formulation are the core development milestones. One view holds that platform potential should be judged by safety and manufacturing reproducibility as well as duration of action and partner decisions.

If partners change their development decisions, the timing of milestones and contract revenue can shift as well.

Revenue concentration and export reliance

Exports accounted for 64.1% of 2025 revenue, so results lean heavily on the progress of overseas contracts. Revenue moves sharply from quarter to quarter depending on a few contracts and licensing timelines. Until the plants are running, fixed costs tied to facilities and staff may keep weighing on the loss structure.

11

What to watch next

  1. Late March 2027

    The 2026 annual report. It is the first regular filing to check full-year 2026 revenue and operating loss and progress toward the 2027 profitability target.

  2. By May 15, 2027

    The Q1 2027 quarterly report. It shows whether quarterly revenue holds up and whether the gap between operating loss and the controlling-shareholder net loss narrows.

  3. During 2027 (completion target)

    Whether the second GMP plant is completed and its lines begin operating. Commercial production capacity is needed to broaden the CDMO revenue base.

  4. During 2027 (timing not disclosed)

    Disclosure of clinical entry for the one-month semaglutide formulation and the multiple-dose Phase 1b study of GB-5001. These show whether the pipeline moves to the next validation stage.

  5. Ongoing during 2027 as disclosed

    Conversion requests and conversion price adjustments for the convertible bond and preferred shares. These filings indicate the common share count and the scale of dilution.

12

Overall view

G2GBIO recorded operating losses for three straight years through 2025, and revenue fell to KRW 423 million that year. The third quarter of 2026 showed an operating loss of KRW 3.43 billion and a controlling-shareholder net loss of KRW 6.43 billion, extending the run of losses to five quarters.

On the other side, the February 2026 raise of KRW 150 billion expanded financial headroom, and the second GMP plant, targeted for completion in 2027, along with partnerships such as Boehringer Ingelheim has become central to the business.

Bullish factors are the wider partner base and production build-out, while bearish factors are the thin revenue base, widening losses and dilution risk. The two sides deserve equal weight, and the key variables are whether clinical validation and contract revenue carry through to reported results.

Valuation rests on pipeline and partnership outcomes, since PER cannot be calculated. The next confirmation points are the 2026 annual report and the Q1 2027 quarterly report, where the narrowing or widening of the gap between operating loss and the controlling-shareholder net loss is a concrete item to check.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. disclo.co.kr
  2. bosoop.com
  3. theviewers.co.kr
  4. etoday.co.kr
  5. sisajournal-e.com
  6. biotimes.co.kr
  7. m.thebell.co.kr
  8. marvellab.maxnmarvel.com
  9. biotimes.co.kr
  10. m.thebell.co.kr
  11. thecoreon.co.kr
  12. mt.co.kr
  13. alphasquare.co.kr
  14. butler.works
  15. moonoks.com
  16. job-post.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis